Establishment and characterization of the gemcitabine‑resistant human pancreatic cancer cell line SW1990/gemcitabine

Yu,Yue; Ding,Fei; Gao,Meng; Jia,Yi  Fu; Ren,Le

doi:10.3892/ol.2019.10627

Establishment and characterization of the gemcitabine‑resistant human pancreatic cancer cell line SW1990/gemcitabine

Authors:
- Yue Yu
- Fei Ding
- Meng Gao
- Yi Fu Jia
- Le Ren
View Affiliations

Affiliations: Department of Gastroenterology, Affiliated Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China
Published online on: July 17, 2019 https://doi.org/10.3892/ol.2019.10627
Pages: 3065-3071
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to its rapid progression, metastasis and resistance to chemotherapy, pancreatic cancer is one of the most malignant tumor types to affect the digestive system. Gemcitabine chemotherapy is typically the first choice of treatment for advanced pancreatic cancer; however, chemoresistance is a major obstacle to successful treatment. In order to elucidate the underlying mechanisms of gemcitabine resistance in pancreatic cancer, the drug‑resistant cell line SW1990‑gemcitabine (SW1990‑GZ) was established using the human pancreatic cancer cell line SW1990. The IC50, resistance index and growth of SW1990 and SW1990‑GZ cells were also assessed using 3‑(4,5‑dimethyl‑2‑thiazolyl)‑2,5‑diphenyl‑2‑H‑tetrazolium bromide (MTT) assays. The cellular uptake of gemcitabine in SW1990 and SW1990‑GZ was measured using high performance liquid chromatography (HPLC). The protein expression of p53 was also assessed by western blot analysis. The results demonstrated that the IC50 of SW1990 and SW1990‑Gz was 0.07±0.0021 and 87.5±3.24 µg/ml, respectively, and that the resistance index ratio of SW1990‑Gz was 1,250. The growth rate of SW1990‑GZ cells was low compared with that of SW1990 cells. The HPLC results indicated that gemcitabine uptake was markedly reduced in SW1990‑GZ cells compared with in SW1990 cells at different time points. The protein expression of p53 was significantly higher in GEM‑resistant SW1990‑GZ cells compared with that in SW1990 cells (P<0.01). These results suggest that a human gemcitabine‑resistant pancreatic cancer cell line was successfully established, with stable and significant drug resistance. The results of the present study suggest that the decreased cellular uptake of gemcitabine may serve an important role in gemcitabine chemoresistance in SW1990‑GZ cells; thus, this cell line may be used as an effective in vitro model to improve our understanding of gemcitabine‑resistance in pancreatic cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, et al: Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 120:1290–1314. 2014. View Article : Google Scholar : PubMed/NCBI
3	Chen YW, Liu JY, Lin ST, Li JM, Huang SH, Chen JY, Wu JY, Kuo CC, Wu CL, Lu YC, et al: Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells. Mol Biosyst. 7:3065–3074. 2011. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
5	D'Angelo F, Antolino L, Farcomeni A, Sirimarco D, Kazemi Nava A, De Siena M, Petrucciani N, Nigri G, Valabrega S, Aurello P and Ramacciato G: Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and meta-analysis. Med Oncol. 34:852017. View Article : Google Scholar : PubMed/NCBI
6	Rakhra S, Strauss JB, Robertson J, McGinn CJ, Kim T, Huang J, Blake A, Helenowski I, Hayes JP, Mulcahy M and Small W Jr: Hypofractionated conformal radiotherapy with concurrent full-dose gemcitabine versus standard fractionation radiotherapy with concurrent fluorouracil for unresectable pancreatic cancer: A multi-institution experience. J Gastrointest Cancer. 47:196–201. 2016. View Article : Google Scholar : PubMed/NCBI
7	Żmijewska-Tomczak M, Milecki P, Olek-Hrab K, Hojan K, Golusiński W, Rucińska A and Adamska A: Factors influencing quality of life in patients during radiotherapy for head and neck cancer. Arch Med Sci. 10:1153–1159. 2014. View Article : Google Scholar : PubMed/NCBI
8	Rajabpour A, Rajaei F and Teimoori-Toolabi L: Molecular alterations contributing to pancreatic cancer chemoresistance. Pancreatology. 17:310–320. 2017. View Article : Google Scholar : PubMed/NCBI
9	Otake A, Tsuji D, Taku K, Kawasaki Y, Yokoi M, Nakamori H, Osada M, Matsumoto M, Inoue K, Hirai K and Itoh K: Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine. Eur J Clin Pharmacol. 73:1033–1039. 2017. View Article : Google Scholar : PubMed/NCBI
10	Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q and Li M: Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets. 15:817–828. 2011. View Article : Google Scholar : PubMed/NCBI
11	Soussi T, Dehouche K and Béroud C: p53 website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis. Hum Mutat. 15:105–113. 2000. View Article : Google Scholar : PubMed/NCBI
12	Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero S, Piazza M, Blandamura S, et al: p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer. 79:425–432. 1997. View Article : Google Scholar : PubMed/NCBI
13	Dhayat SA, Mardin WA, Seggewiß J, Ströse AJ, Matuszcak C, Hummel R, Senninger N, Mees ST and Haier J: MicroRNA profiling implies new markers of gemcitabine chemoresistance in mutant p53 pancreatic ductal adenocarcinoma. PLoS One. 10:e01437552015. View Article : Google Scholar : PubMed/NCBI
14	Mezencev R, Matyunina LV, Wagner GT and McDonald JF: Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes. Cancer Gene Ther. 23:446–453. 2016. View Article : Google Scholar : PubMed/NCBI
15	Elaskalani O, Razak NB, Falasca M and Metharom P: Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer. World J Gastrointest Oncol. 9:37–41. 2017. View Article : Google Scholar : PubMed/NCBI
16	Azmi AS, Bao B and Sarkar FH: Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metastasis Rev. 32:623–642. 2013. View Article : Google Scholar : PubMed/NCBI
17	Ando T, Ichikawa J, Okamoto A, Tasaka K, Nakao A and Hamada Y: Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res. 23:964–969. 2005. View Article : Google Scholar : PubMed/NCBI
18	Hong SP, Wen J, Bang S, Park S and Song SY: CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 125:2323–2331. 2009. View Article : Google Scholar : PubMed/NCBI
19	Qiu H, Fang X, Luo Q and Ouyang G: Cancer stem cells: A potential target for cancer therapy. Cell Mol Life Sci. 72:3411–3424. 2015. View Article : Google Scholar : PubMed/NCBI
20	Bao Q, Zhao Y, Renner A, Niess H, Seeliger H, Jauch KW and Bruns CJ: Cancer stem cells in pancreatic cancer. Cancers (Basel). 2:1629–1641. 2010. View Article : Google Scholar : PubMed/NCBI
21	Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL and Li D: Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 116:5325–5335. 2010. View Article : Google Scholar : PubMed/NCBI
22	Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A and Pastor-Anglada M: Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res. 9:5000–5008. 2003.PubMed/NCBI
23	Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Devière J and Van Laethem JL: Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 15:2913–2919. 2009. View Article : Google Scholar : PubMed/NCBI
24	Nordh S, Ansari D and Andersson R: hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. World J Gastroenterol. 20:8482–8490. 2014. View Article : Google Scholar : PubMed/NCBI
25	Hagmann W, Jesnowski R and Löhr JM: Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 12:740–747. 2010. View Article : Google Scholar : PubMed/NCBI
26	Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR and Blobe GC: TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis. 37:1041–1051. 2016. View Article : Google Scholar : PubMed/NCBI
27	Sheikh R, Walsh N, Clynes M, O'Connor R and McDermott R: Challenges of drug resistance in the management of pancreatic cancer. Expert Rev Anticancer Ther. 10:1647–1661. 2010. View Article : Google Scholar : PubMed/NCBI
28	Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, et al: Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology. 143:664–674.e6. 2012. View Article : Google Scholar : PubMed/NCBI
29	Cascinu S, Graziano F, Del Ferro E, Staccioli MP, Ligi M, Carnevali A, Muretto P and Catalano G: Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. 83:1917–1922. 1998. View Article : Google Scholar : PubMed/NCBI
30	An Y, Yao J, Wei JS, Lu ZP, Cai HH, Dai CC, Qian ZY, Xu ZK and Miao Y: Establish a gemcitabine-resistant pancreatic cancer cell line SW1990/GZ and research the relationship between SW1990/GZ and pancreatic cancer stem cell. Zhonghua Wai Ke Za Zhi. 48:999–1003. 2010.(In Chinese). PubMed/NCBI
31	Niu BZ, Chen G, Li LJ, Wu YD and Zhao YP: Drug resistance and activity changes of thioredoxin reductase in pancreatic cancer cells strain SW1990 induced by gemcitabine. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 27:606–610. 2005.(In Chinese). PubMed/NCBI